Mario Sznol, MD

Professor of Medicine (Medical Oncology); Co-Director, Yale SPORE in Skin Cancer

Clinical Interests

  • Medical Oncology
  • Melanoma

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Cancer Center, Yale: Melanoma Program | Prostate and Urologic Cancers Program

General Urology

Medical Oncology: Subset Medical Oncology Faculty

Medical Oncology

Yale Medical Group

Clinical Trials

Conditions Study Title
Melanoma, skin A Phase I/II, Dose-escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 antibody (Varlilumab) Administered in Combination with Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors (CDX1127-02)
Prostate Genitourinary Cancer Data and Specimen Repository
Unknown Sites Study of Immune System in Patients with Cancer and Blood Disorders
Melanoma, skin Phase I/II study to assess the safety and activity of enhanced TCR transduced autologous T cells against cancer-testis antigens in metastatic melanoma
Bladder, Brain and Nervous System, Breast - Female, Cervix Uteri, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Multiple Myeloma, Non-Hodgkin's Lymphoma, Other Female Genital, Other Male Genital, Pancreas, Prostate, Rectum, Soft Tissue, Stomach, Thyroid A Phase I, Open-label, dose-escalation study of the safety and pharmacokinetics of MPDL3280A administered intravenously as a single agent to patients with locally advanced or metastatic solid tumors or hematologic malignancies
Melanoma, skin Phase I Dose Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients with Advanced Malignancies
Melanoma, skin A Phase 1, Open label, Dose Finding Study to Assess the Safety and Tolerability of IMCgp100, a Monoclonal T Cell Receptor anti-CD3 scFv Fusion Protein in Patients With Advanced Malignant Melanoma.
Colon, Kidney, Lung, Other Digestive Organ, Rectum, Stomach A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH BEVACIZUMAB AND/OR CHEMOTHERAPY IN PATIENTS WITH ADVANCED SOLID TUMORS
Lung, Melanoma, skin A Phase 2 Study of MK-3475 in patients with metastatic melanoma and non-small cell lung cancer with untreated brain metastases
The Yale School of Medicine Melanoma Patient Registry
Active Surveillance of the Small Renal Mass: An Integrated Biomarker Trial
Melanoma, skin A PHASE 1b STUDY OF THE 4-1BB AGONIST PF-05082566 IN COMBINATION WITH THE PD-1 INHIBITOR MK-3475 IN PATIENTS WITH ADVANCED SOLID TUMORS
Lung, Melanoma, skin A Phase I/II Trial of Evaluating the Combination of MK-3475 and Stereotactic Body Radiotherapy in Patients with Metastatic Melanoma or NSCLC
Melanoma, skin Stand Up To Cancer Consortium - Genomics-Enabled Medicine for Melanoma (G.E.M.M.): Using Molecularly-Guided Therapy for Patients with BRAF wild-type (BRAFwt) Metastatic Melanoma
Other Skin Phase II Study of MK-3475 in Patients with Advanced Merkel Cell Carcinoma
Kidney A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
Soft Tissue Phase 1 Study of Mogamulizumab (KW-0761) in Combination with MEDI4736 and Mogamulizumab in Combination with Tremelimumab in Subjects with Advanced Solid Tumors
Soft Tissue A PHASE I, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF MOXR0916 ADMINISTERED INTRAVENOUSLY AS A SINGLE AGENT TO PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS
Melanoma, skin A Phase 1, Open-Label, Multicenter, Multi-Dose Escalation Study of CM-24 in Subjects with Selected Advanced or Recurrent Malignancies
A Phase 1, Open Label, Dose Escalation Study of MGA271 (Fc-optimized Humanized Anti-B7-H3-Expressing Neoplasms or Neoplasms Whose Vasculature Expresses B7-H3

Edit this profile

Contact Info

Mario Sznol, MD
Patient Care Location
Smilow Cancer Hospital at Yale-New HavenSmilow Cancer Hospital at Yale - New Haven
35 Park Street, Ste North Pavilion 8

New Haven, CT 06511
Mailing Address
PO Box 208028
333 Cedar Street

New Haven, CT 06520-8028